Last updated: August 1, 2026
ATROPEN is a single-dose atropine autoinjector used for emergency treatment of poisoning from organophosphate nerve agents and insecticides. Its commercial value is concentrated in military, government stockpiles, emergency-response systems and selected occupational-risk markets rather than routine outpatient prescribing. No current clinical development program appears to be directed at ATROPEN as a branded product, and no material branded-drug exclusivity remains. Market growth depends primarily on public procurement, replenishment cycles, regulatory readiness and competition from combination autoinjectors such as DuoDote and ATNAA.
What is ATROPEN and what is it used for?
ATROPEN is an atropine sulfate autoinjector manufactured historically by Meridian Medical Technologies, a subsidiary of Emergent BioSolutions. It delivers atropine intramuscularly without requiring a syringe or vial.
Atropine is an anticholinergic drug that blocks muscarinic effects caused by organophosphate exposure. The product is intended for emergency use after exposure to:
- Nerve agents, including sarin, soman, tabun and VX
- Organophosphate pesticides
- Other cholinergic toxicants producing muscarinic symptoms
Symptoms may include excessive salivation, lacrimation, bronchial secretions, bronchospasm, bradycardia, vomiting, diarrhea, urination and respiratory failure. ATROPEN does not replace airway management, seizure control or oxime therapy where pralidoxime is indicated. The FDA labeling instructs users to seek emergency medical care after administration. [1]
What strengths does ATROPEN have?
The product has historically been supplied in four dosage strengths:
| ATROPEN strength |
Typical labeled population context |
| 0.25 mg |
Small children |
| 0.5 mg |
Children |
| 1 mg |
Older children and adults |
| 2 mg |
Adults and larger patients |
The appropriate dose depends on age, body weight, exposure severity and medical direction. The product is administered intramuscularly through clothing when necessary, subject to the instructions in the applicable labeling. [1]
What is the FDA regulatory status of ATROPEN?
ATROPEN is an FDA-approved atropine delivery product, not a new chemical entity. FDA approval covers the autoinjector presentation and its labeled emergency-use indication. The active ingredient, atropine sulfate, has been used clinically for decades and is available in multiple injectable products.
The FDA’s public databases should be used to distinguish between:
- Approval of the ATROPEN product;
- Current commercial marketing;
- Availability of the product in federal or institutional procurement channels; and
- Approval of alternative atropine or atropine-pralidoxime products.
A product can remain an approved drug in FDA records while having limited commercial distribution or a discontinued marketing status. ATROPEN’s business position is therefore better assessed through current labeling, federal procurement records, distributor listings and manufacturer disclosures than through approval status alone.
Does ATROPEN have FDA exclusivity?
No meaningful period of new-drug exclusivity remains. Any original FDA exclusivity associated with the historical approval would have expired decades ago. ATROPEN’s current market protection, if any, comes from manufacturing capability, device know-how, procurement contracts, regulatory maintenance and supply reliability.
Atropine itself has no modern composition-of-matter protection. The principal commercial barriers are operational rather than molecular.
Are there clinical trials for ATROPEN?
No active, late-stage clinical program centered on branded ATROPEN is publicly established. Atropine has been evaluated in many clinical settings, including cardiac resuscitation, ophthalmology, toxicology and anesthesia, but those studies do not establish a clinical development program for the ATROPEN brand.
What clinical evidence supports ATROPEN?
The clinical rationale is based on:
- The established pharmacology of atropine;
- Historical treatment of organophosphate poisoning;
- Animal and human toxicology evidence;
- Military and emergency-response experience; and
- FDA review of the autoinjector’s dose delivery and usability.
Randomized controlled trials in deliberate nerve-agent poisoning are not feasible. Evidence is therefore drawn from toxicology practice, controlled exposure models, case reports, emergency medicine protocols and government preparedness programs. The key clinical endpoint is rapid reversal of muscarinic toxicity, especially bronchial secretion, bronchospasm and bradycardia.
Is atropine being studied in new indications?
Atropine continues to appear in clinical trials for non-ATROPEN uses. These studies may involve:
- Bradycardia and cardiac arrest protocols;
- Pediatric airway or anesthesia applications;
- Ophthalmic formulations;
- Neurologic and autonomic disorders; and
- Organophosphate poisoning treatment strategies.
Those studies do not automatically support ATROPEN because the delivery system, dose, route and use environment differ.
What patents protect ATROPEN?
The original patent estate associated with ATROPEN is effectively mature. Any early patents covering atropine formulations, autoinjector structures or emergency-use packaging would generally have expired, absent unusual patent-term adjustments or later improvements.
Are there active formulation patents for ATROPEN?
No commercially significant, publicly established formulation patent moat is apparent for the historical atropine sulfate product. Atropine sulfate is an old active pharmaceutical ingredient, and the formulation is relatively conventional compared with complex biologics, long-acting injectables or drug-device combination products.
Potentially relevant rights could include:
- Autoinjector mechanical architecture;
- Needle-shield or activation systems;
- Packaging and shelf-life controls;
- Device manufacturing methods;
- Training systems;
- Combination-product configurations; and
- Improvements to atropine-pralidoxime delivery.
These rights would not necessarily protect the original ATROPEN product. They would have to be assessed by patent family, claim scope, terminal disclaimers, prosecution history and current ownership.
What is the Orange Book status of ATROPEN?
ATROPEN’s Orange Book position is not equivalent to an active, protected branded prescription market. The Orange Book records approved drug products and certain patent and exclusivity information, but listing status can change when a product is discontinued, transferred or no longer marketed.
A generic applicant seeking approval for an equivalent atropine autoinjector would need to address the applicable FDA product requirements and any active listed patents. The absence of meaningful remaining exclusivity would favor an abbreviated regulatory pathway if an equivalent reference product and suitable product-specific requirements are available.
When does ATROPEN lose exclusivity?
ATROPEN’s original exclusivity has already expired. The product does not have the commercial profile of a recently approved therapy protected by:
- Five-year new chemical entity exclusivity;
- Three-year clinical-investigation exclusivity;
- Seven-year orphan-drug exclusivity;
- Pediatric exclusivity; or
- Patent-protected biologic exclusivity.
The relevant question is not when ATROPEN loses exclusivity, but whether a manufacturer can obtain approval, qualify the device, validate shelf life and compete for procurement contracts.
Which companies compete with ATROPEN?
ATROPEN competes in two distinct markets: standalone atropine autoinjectors and combination nerve-agent antidote products.
| Competitor or alternative |
Product type |
Strategic position |
| DuoDote |
Atropine plus pralidoxime chloride autoinjector |
Integrated antidote for organophosphate and nerve-agent exposure |
| ATNAA |
Atropine and pralidoxime autoinjector |
Military and government countermeasure product |
| Generic atropine injection |
Vial or prefilled syringe |
Lower-cost clinical alternative, but less suitable for immediate field use |
| Pharmacy-compounded or institutional kits |
Manual delivery systems |
Used where autoinjector procurement is unavailable |
| Other atropine autoinjector suppliers |
Drug-device combinations |
Potential competitors subject to FDA and procurement requirements |
DuoDote and ATNAA have a functional advantage in situations where pralidoxime is required. ATROPEN has a simpler product profile because it delivers atropine alone and can be used as an initial response to muscarinic toxicity.
What is the market size for ATROPEN?
There is no reliable public, standalone revenue estimate for ATROPEN. Manufacturer disclosures generally combine countermeasure products with broader pharmaceutical, medical-device or government-contract revenue. Public market reports also tend to group atropine, nerve-agent antidotes, emergency injectors and chemical-biological defense products into wider categories.
The addressable market is best divided into four segments:
| Segment |
Demand driver |
Revenue quality |
| U.S. federal procurement |
National stockpile replenishment and preparedness contracts |
Large but lumpy |
| Defense and allied governments |
Military deployment and strategic reserves |
Contract-driven |
| Civilian emergency response |
Fire departments, hazardous-material teams and hospitals |
Fragmented |
| Occupational and agricultural exposure |
Pesticide-risk management |
Smaller and geographically variable |
Government demand can produce large purchase orders, but annual revenue is volatile. Stockpiling reduces recurring prescription volume, while expiration dating creates periodic replacement demand.
What is the ATROPEN market projection?
A defensible product-specific dollar forecast is not available from public disclosures. A scenario forecast is more appropriate than a false precision estimate.
Base-case market outlook through 2030
The ATROPEN addressable market is likely to remain stable to modestly growing through 2030, with demand shaped by:
- Replacement of expiring government inventories;
- Heightened chemical-defense preparedness;
- New or renewed federal contracts;
- Expansion of emergency-response inventories;
- Competition from atropine-pralidoxime combination devices; and
- Manufacturing and supply continuity.
| Scenario |
Market direction through 2030 |
Primary assumption |
| Downside |
Decline |
Procurement shifts to combination products or manual injectable stock |
| Base case |
Low-single-digit annual growth in addressable demand |
Stable government replenishment and selective civilian adoption |
| Upside |
Mid-single-digit or higher growth in procurement demand |
New national stockpiles, geopolitical risk or expanded allied purchases |
These rates describe the likely direction of the addressable countermeasure category, not verified ATROPEN product sales. ATROPEN’s own share could decline even if the broader category expands.
What patent litigation affects ATROPEN?
No major, current patent litigation involving ATROPEN is publicly established as a central market event. The product’s mature patent position reduces the likelihood of high-value litigation over basic atropine composition or use claims.
Potential disputes would more likely involve:
- Autoinjector device claims;
- Manufacturing and assembly methods;
- Drug-device combination approval;
- Government-contract performance;
- Supply and quality obligations;
- Trademark or product-name rights; and
- Competing products seeking FDA approval.
Litigation risk is therefore lower than for patented oncology drugs, biologics or extended-release products. Regulatory and procurement disputes are more commercially relevant than Paragraph IV litigation.
Are there Paragraph IV challenges to ATROPEN?
No material current Paragraph IV challenge is publicly associated with ATROPEN as a major branded market. Paragraph IV litigation requires an ANDA applicant to challenge a listed patent for a reference product. Because ATROPEN’s market protection is mature and its product-specific regulatory pathway may be complex, the main obstacle is likely development and approval of an equivalent autoinjector rather than patent invalidation.
A future applicant could face technical requirements involving:
- Dose accuracy;
- Injection depth and delivery time;
- Human factors;
- Device reliability;
- Stability and shelf life;
- Container-closure integrity;
- Extractables and leachables;
- Sterility or microbial controls; and
- Labeling for emergency use.
What manufacturing and intellectual-property barriers exist?
ATROPEN’s main barriers are manufacturing and regulatory execution.
A credible supplier must maintain:
- Atropine sulfate API qualification;
- Sterile or controlled drug-product manufacturing;
- Autoinjector assembly capacity;
- Device-component supply;
- Human-factors validation;
- Stability data across required storage conditions;
- Lot-release testing;
- Combination-product quality systems; and
- Surge capacity for government orders.
The largest commercial risk is supply concentration. A product may have weak patent protection yet remain difficult to replace because few manufacturers can deliver validated autoinjectors at the scale and readiness required by government buyers.
How strong is the ATROPEN patent estate?
The patent estate is weak as a long-term exclusivity platform but potentially meaningful as a product-execution platform. Basic atropine chemistry provides little protection. Device patents, process controls, regulatory data and procurement relationships can still create practical barriers.
| Factor |
Assessment |
| Active ingredient protection |
Very weak or expired |
| New-drug exclusivity |
Expired |
| Formulation protection |
Limited |
| Device protection |
Potentially relevant only for specific claims and ownership |
| Regulatory complexity |
Moderate to high |
| Government-contract advantage |
Potentially significant |
| Switching barriers |
Moderate in stockpile programs |
| Litigation exposure |
Lower than for patent-heavy branded drugs |
What generic launch risks exist?
A generic or alternative supplier could enter if it can establish pharmaceutical equivalence, device performance and acceptable labeling. Launch timing would depend more on FDA review and contracting than on patent expiry.
The main launch risks are:
- Lack of a suitable reference-product pathway;
- Autoinjector human-factors failures;
- Inadequate shelf-life data;
- Device component shortages;
- Low commercial volume outside government contracts;
- Entrenched procurement specifications;
- Requirement for large inventory commitments; and
- Competition from combination antidote devices.
A lower-priced entrant may not displace an incumbent if the incumbent has superior delivery reliability, stockpile qualification or contract access.
What licensing deals affect ATROPEN?
No major recent licensing transaction has publicly redefined the ATROPEN market. The product’s commercial history is tied more closely to corporate ownership, government contracting and portfolio transactions than to a high-value drug licensing model.
Potential licensing value would center on:
- Autoinjector technology;
- Chemical-biological defense portfolios;
- Government procurement rights;
- Manufacturing transfer;
- International distribution;
- Combination-product development; and
- Strategic stockpile supply.
Key Takeaways
- ATROPEN is an atropine sulfate autoinjector for organophosphate and nerve-agent poisoning.
- No active branded clinical development program is publicly established for ATROPEN.
- Original drug exclusivity and basic composition protection have expired.
- The product’s commercial value is concentrated in government, defense and emergency-response procurement.
- DuoDote and ATNAA are important combination-product competitors.
- No material current Paragraph IV or patent litigation event defines the market.
- Market demand is likely to remain stable to modestly increasing through 2030, but product-specific revenue is highly dependent on procurement awards.
- Manufacturing validation, device reliability, shelf life and government contracting are more important than conventional pharmaceutical patent protection.
- ATROPEN’s strongest practical defenses are supply capability, regulatory readiness and procurement relationships.
FAQs
Is ATROPEN still commercially available?
Availability depends on current manufacturer distribution, federal procurement and regional suppliers. Historical FDA approval does not guarantee continuous retail availability.
Is ATROPEN the same as DuoDote?
No. ATROPEN delivers atropine alone. DuoDote delivers atropine together with pralidoxime chloride in a single autoinjector.
Can generic atropine injection replace ATROPEN?
Generic atropine injection can provide the same active ingredient but does not provide the same rapid, field-ready autoinjector delivery system.
Does ATROPEN treat pesticide poisoning?
It is labeled for emergency treatment of poisoning by organophosphate nerve agents and insecticides. Medical evaluation and additional treatment may be required.
Is ATROPEN a biologic or biosimilar product?
No. ATROPEN is a small-molecule drug-device combination. Biosimilar rules do not apply.
References
-
U.S. Food and Drug Administration. (n.d.). ATROPEN atropine injection, auto-injector prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drug products. FDA.
-
U.S. Department of Defense. (n.d.). Chemical, biological, radiological and nuclear medical countermeasures. U.S. Department of Defense.
-
National Library of Medicine. (n.d.). DailyMed: Atropine sulfate injection labeling. U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
